Vladimir Roudko

Just heard the brilliant news that AlphaFold was awarded the lasker award- congratulation to Deemis Hassabis & team for a well deserved recognition laskerfoundation.org/winners/alphaf…

Today we launch the next generation of AI oncology company with the support of great investors @hardimanjames @DCVC, @dreidco @ZettaVentures, 11.2, Intermountain Ventures, Epic Ventures, Catalio, North South Ventures, @viswacolluru @RecursionChris. businesswire.com/news/home/2023…

New generation of cancer-preventing vaccines enter early clinical trials for healthy people at high risk for disease #cancer #Immunotherapy science.org/content/articl…

Storing and analyzing a genome on a blockchain genomebiology.biomedcentral.com/articles/10.11…

The @bernstein_lab is now on #Twitter! Follow us for lab updates and news on cancer epigenetics!! 🧬🔬

New updated analysis by the team at @CancerResearch in collaboration with @IQVIA_global of the PD1/PDL1 clinical trial landscape, including use of approved therapies in the clinic and a summary of new anti-PD1/PDL1 treatment modalities go.nature.com/3HIpHPm

Great news!

The new @EMBL Programme has launched! We're proud to be a part of @EMBL and we're looking forward to contributing our #bioinformatics expertise to this exciting new scientific programme that ushers in a new era in the life sciences.

Why sequence all eukaryotes? pnas.org/content/119/4/…

A study evaluating effectiveness of the BNT162b2 (Pfizer-BioNTech) vaccine against the #Omicron variant indicates a third dose neutralizes Omicron at a similar order of magnitude as was observed after two doses of the vaccine against wild-type #SARSCoV2. fcld.ly/d9noexp

Specialized ribosomes go immune! Role of protein translation in immunotherapy response and evasion gets first recognition.

MEFISTO is out in Nature Methods - a framework for dimension reduction and integration of multi-modal omics data with temporal or spatial resolution. Paper at nature.com/articles/s4159…, highlights in the thread below. (1/7)

(1) Finally out, after one of the most painful and long reviews (with nitpicky reviews, see my last comment) is a method that I am extremely proud of and excited about. One of the best in my career: nature.com/articles/s4159…

How does that even make any sense?

Excited to share my work from @DASLab_MSKCC lab out today in @nchembio where we develop CAR-T cells that produce small molecule drugs at the tumor site. This is an exciting step forward in the utilization of engineered cells for drug delivery! nature.com/articles/s4158…

Studying ~56 million T cells from 55 COVID patients, researchers in @SciImmunology offer a high-res picture of epitope reactivity and TCR usage in CD8 T cells specific for #SARSCoV2, some of which also react to “common cold” coronaviruses. fcld.ly/s5bda4r

Highly recommended review! 🤯😍😍👏 Germinal Centre Shutdown frontiersin.org/article/10.338…

A new method developed to reread a single polypeptide many times overcomes one of the biggest obstacles toward single-molecule proteomics. Read more in a new #SciencePerspective: fcld.ly/23d7ov4

Findings from the KEYNOTE-522 trial show the addition of the immunotherapy agent pembrolizumab to chemotherapy before surgery decreased the recurrence by almost 40% in patients with early triple-negative breast cancer. #TNBC bit.ly/3yXPUGd

Protein modifications throughout the lung cancer proteome unravel the cancer-specific regulation of glycolysis dlvr.it/SFrY1K